Carteolol
OCUPRESS
What it isNon-selective beta blocker eye drop with intrinsic sympathomimetic activity; glaucoma.
Why this oneThe partial agonism gives a slightly better lipid and heart-rate profile than timolol.
What limits itSystemic beta blockade still occurs. Avoid in asthma and heart block.
FDA-approved for
- open-angle glaucoma / ocular hypertension
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Elevated intraocular pressure / open-angle glaucoma | Adults | 1 drop affected eye(s) BID | 1 drop BID |
Renal Undefined
Hepatic Undefined
Instructions
- Instill 1 drop of 1% solution in affected eye(s) twice daily
Available strengths
- drops 1 %
- sol 10 mg/mL
Contraindications
- Bronchial asthma or history of asthma
- Severe COPD
- Sinus bradycardia
- Second- or third-degree AV block
- Overt cardiac failure
- Cardiogenic shock
Cautions
- Systemic beta-blockade from ophthalmic absorption (bradycardia, hypotension)
- Bronchospasm in bronchospastic disease
- May mask hypoglycemia in insulin-dependent diabetics
- Cardiac/respiratory failure
Adverse reactions
- Transient ocular irritation/burning/tearing
- Conjunctival hyperemia/edema
- Systemic: bradycardia, decreased blood pressure
Pregnancy Undefined
Lactation Undefined
Cost
Carteolol (OCUPRESS)
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 1 % | drops | per unit | not offered |
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Carteolol is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Generic entry2000
NO BOXED WARNINGS
Principal riskSystemic beta blockade from eye drops
Classes and tags
Clinical profile
Legacy pregnancy categoryC
Defining liabilityBradycardia, hypotension and bronchospasm; overdose may cause conduction block or cardiogenic shock.